Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO for Stem Cell Mobilization in Acute Leukemia
NCT06955858Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label, single-arm trial of recombinant human thrombopoietin in acute leukemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Total CD34+ cell count at 2 weeks. Planned start May 2025; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT06955858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955858.